Back to Stakeholders
Independent Academic Research Groups

Idorsia Pharmaceuticals Ltd.

Switzerland
1 Trial

Idorsia Pharmaceuticals Ltd. is a Swiss publicly traded biopharmaceutical company (spun out of Actelion in 2017) focused on developing medicines for high-unmet-need conditions, with products including the dual orexin receptor antagonist daridorexant (Quviviq) for insomnia. Idorsia is a participating organization in the U.S. Department of Defense PTSD Adaptive Platform Trial, which evaluates multiple therapeutic interventions — including the intranasal ketamine compound SLS-002 — for veterans with treatment-resistant PTSD.

Quick Facts

Type
Public Biotech
HQ
Switzerland
Website
Visit

Collaborated Trials

1
Not yet recruitingII

Department of Defense PTSD Adaptive Platform Trial – Intervention D – SLS-002

Start Date
Compounds
Ketamine, Placebo